Clinical Trial Detail

NCT ID NCT02494583
Title Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Capecitabine

Cisplatin + Fluorouracil

Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST